Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients
Author:
Funder
National Key R&D Program of China
National Natural Science Foundation of China
National High-Tech R&D Program
Publisher
Elsevier BV
Subject
Multidisciplinary
Reference39 articles.
1. Prospective Phase II study of gefitinib for chemotherapy-naïve patients with advanced non–small-cell lung cancer with epidermal growth factor receptor gene mutations;Inoue;J. Clin. Oncol.,2006
2. First-line gefitinib in patients with advanced non–small-cell lung cancer harboring somatic EGFR mutations;Sequist;J. Clin. Oncol.,2008
3. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol.,2012
4. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol.,2010
5. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures;Lee;Pharmacol. Ther.,2017
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?;Journal of Clinical Medicine;2023-02-10
2. Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer;Diagnostics;2022-07-25
3. Prevalence of targeted therapy-related genetic variations in NSCLC and their relationship with clinicopathological characteristics;PLOS ONE;2022-01-21
4. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study;Targeted Oncology;2021-02-05
5. The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden;Journal of Medical Economics;2021-01-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3